Out-of-the-box thinking leads to potential glaucoma treatment

May 3, 2016
Novel compounds may have potential for other eye diseases.

Mice with glaucoma, which were treated with a compound developed by researchers in Japan, showed signs that the treatment prevented or retarded damage to the nerves that cause blindness.

That was one of the findings in a study reported April 19 in the online journal Heliyon on the "Neuroprotective effects of VCP modulators in mouse models of glaucoma" by researchers at Kyoto University.

The novel, synthesized compounds—called Kyoto University Substances (KUSs)—inhibited the activities of valosin-containing proteins (VCP) and mitigated the death of retinal ganglion cells (RGCs), the researchers say. Over time, RGCs die in patients with glaucoma. There is no cure for glaucoma, but early diagnosis and treatment can preserve sight.

"In conclusion, KUSs (Kyoto University Substances) could provide convenient, novel therapeutics for neuroprotection in incurable eye diseases such as glaucoma," wrote researcher and study author Noriko Nakano. "Given that the major pathology of many incurable human disorders, e.g., neurodegenerative diseases, ischemic diseases, etc., is early cell death in the affected organs, which occurs long before somatic death, KUSs could also provide a novel strategy for cell protection in these disorders."

The research is promising, says Murray Fingeret, O.D., chief of optometry at the U.S. Department of Veterans Affairs, New York Harbor Healthcare System, in Brooklyn, New York. Dr. Fingeret is the first and only doctor of optometry appointed to the board of directors of The Glaucoma Foundation, where he continues his life's work of research and collaboration into finding a cure.

He applauded the researchers for their out-of-the box thinking.

"Most agents that are being evaluated for glaucoma neuroprotection have come from medications used for neurologic conditions such as Alzheimer's disease, dementia and traumatic brain injury because there are similar final pathways in terms of how nerve cells die, though their origins are different," Dr. Fingeret says.

But more research needs to be done. Animal models don't easily translate to human beings, he says.

"Animal models typically use 'crush' models in which the optic nerve is crushed and histologic sections used," Dr. Fingeret says. "This is a very different method to determine outcomes than what is used clinically, such as monitoring the optic nerve or visual fields. Positive results in animal models rarely turn into commercially viable drugs. There are no approved neuroprotection agents, for example, though similar animal model results have been previously reported."

The AOA follows all research closely, including potential glaucoma treatments. Although KUSs are an interesting treatment possibility for patients, more research is needed regarding their influence on visual health.

Related News

AOA series addresses concerns about myopia management

With the prevalence of myopia on the rise worldwide, an AOA webinar attempts to erase concern over barriers to providing myopia management. The webinar kicked off a three-event series focused on raising awareness of myopia management as a standard of care especially for children. Next is “Meet the Myopia Experts” on Saturday, June 24, at Optometry’s Meeting® 2023 in Washington, D.C.

AOA serving patients through research in optometry

For the fifth consecutive year, the AOA is sponsoring the Investigator Initiated Research Award. Investigators are invited to electronically submit proposals by July 1 for projects designed to increase knowledge through basic clinical and/or translational science relative to the continuum of eye and vision care. The AOA provides a maximum of $50,000 in direct costs for research conduct. Eric Ritchey, O.D., Ph.D., talks about his current research on low-level light therapy for patients with meibomian gland dysfunction, which can lead to dry eye disease.

Marijuana sensibilities changing fast: Are you ready for patients’ questions?

Public support for marijuana legalization has never been higher in the U.S., but evidence of its clinical utility in glaucoma care remains clouded at best.